$0.77
12.11% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Polyrizon Stock price

$0.88
-0.50 36.14% 1M
-0.67 43.14% 6M
-1.29 59.39% YTD
-0.67 43.14% 1Y
-0.67 43.14% 3Y
-0.67 43.14% 5Y
-0.67 43.14% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.26%
ISIN
IL0011814113
Symbol
PLRZ
Sector
Industry

Key metrics

Market capitalization $3.70m
Enterprise Value $4.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-657.00k
Free Cash Flow (TTM) Free Cash Flow $-540.00k
EPS (TTM) EPS $-0.24

Is Polyrizon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Financial data from Polyrizon

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 0.35 0.35
5% 5%
-
- Research and Development Expense 0.30 0.30
11% 11%
-
-0.65 -0.65
2% 2%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -0.66 -0.66
1% 1%
-
Net Profit -1 -1
163% 163%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polyrizon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polyrizon Stock News

Neutral
GlobeNewsWire
29 days ago
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on...
Neutral
GlobeNewsWire
about one month ago
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
Neutral
GlobeNewsWire
2 months ago
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of...
More Polyrizon News

Company Profile

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Head office Israel
CEO Tomer Izraeli
Founded 2005
Website polyrizon-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today